COVID-19's Effect on Biopharma M&As in 2020

Although they don’t necessarily agree on numbers, most reports indicate that 2020 was not a particularly good year for mergers and acquisitions (M&As) in the biopharma industry. Some of that disagreement on numbers is likely related to how they are defining sectors—healthcare versus biotech and pharmaceutical, for example. But everyone agrees that the uncertainty and devastation caused by the COVID-19 pandemic had a major dampening effect on deal-making in 2020. Here’s a look.